Login to Your Account



‘Ear’ Comes Otonomy: Series C Nets $45.9M for Program Trio

By Randy Osborne
Staff Writer

Thursday, September 5, 2013
Otonomy Inc.’s $45.9 million Series C round should last the firm into the second half of 2014, when one of its ear disease drugs is expected to be ready for a new drug application filing, another will have finished the first of a pair of pivotal trials and a third will be eligible for an investigational new drug application.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription